|Articles|January 1, 1998

Novopharm fined $1.25 million for contempt of court

In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.

In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.

Novopharm was fined for failure to comply with a court order to disclose documents pertaining to the drug Lovastatin, for secretly resuming research on the product and for making submissions to the government using illegally retained documents.

According to a statement issued by Associate Chief Justice Oliphant, Novopharm's actions were motivated by a desire to bring Lovastatin to market before rival products, such as those produced by pharmaceutical company Apotex Inc. "The contemptuous conduct here was, I believe…fueled by what must be one of the most bitter business rivalries I have ever witnessed," Oliphant said.

In the past, Novopharm was held liable for misappropriation of technology from a fermentation facility in Winnipeg owned by Apotex.

As a result, Novopharm cannot use the technology and was ordered to pay damages to Apotex in the amount of $6.5 million.

In addition to the most recent fine of $1.25 million, the court also ordered Novopharm to pay all of the legal costs that Apotex incurred as a result of the contempt proceedings. PR


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.